Top-Rated StocksTop-RatedNASDAQ:QURE uniQure (QURE) Stock Forecast, Price & News $6.45 -0.26 (-3.87%) (As of 11:27 AM ET) Add Compare Share Share Today's Range$6.40▼$6.7450-Day Range$6.71▼$10.6252-Week Range$6.40▼$28.25Volume165,774 shsAverage Volume789,830 shsMarket Capitalization$307.69 millionP/E RatioN/ADividend YieldN/APrice Target$44.70 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media uniQure MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside566.2% Upside$44.70 Price TargetShort InterestBearish8.59% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 3 Articles This WeekInsider TradingSelling Shares$215,303 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.61) to ($5.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.21 out of 5 starsMedical Sector416th out of 969 stocksPharmaceutical Preparations Industry180th out of 454 stocks 3.5 Analyst's Opinion Consensus RatinguniQure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $44.70, uniQure has a forecasted upside of 566.2% from its current price of $6.71.Amount of Analyst CoverageuniQure has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.59% of the float of uniQure has been sold short.Short Interest Ratio / Days to CoveruniQure has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in uniQure has recently increased by 60.76%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YielduniQure does not currently pay a dividend.Dividend GrowthuniQure does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QURE. Previous Next 2.4 News and Social Media Coverage News SentimentuniQure has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for uniQure this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for QURE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows23 people have added uniQure to their MarketBeat watchlist in the last 30 days. This is an increase of 475% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $215,303.00 in company stock.Percentage Held by InsidersOnly 3.73% of the stock of uniQure is held by insiders.Percentage Held by Institutions73.87% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for uniQure are expected to grow in the coming year, from ($5.61) to ($5.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of uniQure is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of uniQure is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiouniQure has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About uniQure (NASDAQ:QURE) StockuniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Read More QURE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QURE Stock News HeadlinesSeptember 30, 2023 | americanbankingnews.comuniQure (NASDAQ:QURE) Stock Price Crosses Below Two Hundred Day Moving Average of $14.56September 22, 2023 | americanbankingnews.comuniQure (NASDAQ:QURE) Receives Consensus Rating of "Buy" from BrokeragesOctober 2, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. July 17, 2023 | seekingalpha.comuniQure: The AMT-130 ReadoutMay 22, 2023 | seekingalpha.comMarket Is Still Not Pricing In The FDA And EU EMA Approvals For uniQureMay 20, 2023 | seekingalpha.comuniQure: Financials And Pipeline Signal A Promising Outlook For InvestorsFebruary 7, 2022 | globenewswire.comuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease - GlobeNewswireFebruary 7, 2022 | finance.yahoo.comuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s DiseaseOctober 2, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. February 5, 2022 | washingtonpost.comWith CRISPR gene editing, unique treatments begin to take off for rare diseases - The Washington PostFebruary 4, 2022 | finance.yahoo.comGlobal Gene Therapy for Blood Disorders Market worth US$ 5.79 Billion by 2030 - Exclusive Report by InsightAce Analytic - Yahoo FinanceFebruary 4, 2022 | marketscreener.comEAHAD 2022 - Final Analysis from the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-State Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Sever or Moderately Severe Hemophilia B - Marketscreener.comFebruary 4, 2022 | axios.com5 unique date ideas in NW Arkansas - AxiosFebruary 4, 2022 | reuters.comAmazon has a unique inflation problem - ReutersFebruary 3, 2022 | chicago.suntimes.comBears hope Justin Fields ‘skyrockets’ — but his rookie struggles weren’t unique - Chicago Sun-TimesFebruary 3, 2022 | washingtonpost.comTurkey's Recep Tayyip Erdogan is the latest leader to visit Ukraine - The Washington PostFebruary 3, 2022 | nj.comUnique soap shop franchise to make N.J. debut - NJ.comFebruary 2, 2022 | forbes.comLooking To Fill Unique Sports Merchandise Void, ‘Official League’ Launches Lifestyle Brand - ForbesFebruary 2, 2022 | bbc.comDeliberate infections give unique Covid insight - BBC NewsJanuary 31, 2022 | pymnts.comWhat Makes the UE’s Digital Markets Act Unique - pymnts.comJanuary 31, 2022 | patriotswire.usatoday.comBill Belichick has unique hiring opportunities if everyone swallows their pride - Patriots WireJanuary 31, 2022 | nj.comChicken-filled waffle cones are coming to N.J. at this unique new eatery - NJ.comJanuary 31, 2022 | abcnews.go.comReview: Unique narrator propels 'What the Fireflies Knew' - ABC NewsJanuary 31, 2022 | globenewswire.comUNIUM Produces Unique Influencer NFT in Its Marketplace - GlobeNewswireJanuary 28, 2022 | saintswire.usatoday.comHow Sean Payton helped save the Saints, and build a unique bond with fans - Saints WireJanuary 27, 2022 | forbes.comSmall Business Owners Have A Truly Unique Roth Contribution Opportunity! - ForbesJanuary 27, 2022 | nj.comBurlington County Open wrestling tournament unique in South Jersey - nj.comSee More Headlines Receive QURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter. Email Address QURE Company Calendar Last Earnings8/01/2023Today10/02/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:QURE CUSIPN/A CIK1590560 Webwww.uniqure.com Phone(120) 240-6000Fax31-20-566-9272Employees501Year FoundedN/APrice Target and Rating Average Stock Price Forecast$44.70 High Stock Price Forecast$57.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+566.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,790,000.00 Net Margins-166.83% Pretax Margin-168.24% Return on Equity-44.91% Return on Assets-25.61% Debt Debt-to-Equity Ratio0.29 Current Ratio11.07 Quick Ratio10.92 Sales & Book Value Annual Sales$106.48 million Price / Sales3.01 Cash FlowN/A Price / Cash FlowN/A Book Value$10.17 per share Price / Book0.66Miscellaneous Outstanding Shares47,700,000Free Float45,925,000Market Cap$320.07 million OptionableOptionable Beta1.06 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Matthew Craig Kapusta (Age 51)CEO & Exec. Director Comp: $1.16MDr. Ricardo Dolmetsch Ph.D. (Age 54)Pres & Chief Scientific Officer Comp: $911.07kMr. Christian Klemt (Age 50)CFO, Principal Financial Officer & GM of Amsterdam Site Comp: $566.36kMr. Pierre Caloz (Age 51)Chief Operating Officer Comp: $951.1kProf. Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-GermanyDr. Jeannette Potts J.D. (Age 61)Ph.D., Chief Legal & Compliance Officer Dr. Tamara Tugal Ph.D.MBA, Bus. Devel. DirectorMs. Erin BoyerChief People & Culture OfficeMs. Maria E. Cantor (Age 55)Chief Corp. Affairs Officer Mr. Richard Porter Ph.D.Chief Bus. OfficerMore ExecutivesKey CompetitorsApollomicsNASDAQ:APLMArbutus BiopharmaNASDAQ:ABUSOrganogenesisNASDAQ:ORGOErascaNASDAQ:ERASAmarinNASDAQ:AMRNView All CompetitorsInsiders & InstitutionsRicardo DolmetschSold 5,841 sharesTotal: $43,573.86 ($7.46/share)Wolverine Trading LLCBought 27,000 shares on 8/23/2023Ownership: 0.000%Coppell Advisory Solutions LLCBought 3,758 shares on 8/17/2023Ownership: 0.008%Nuveen Asset Management LLCBought 1,552 shares on 8/16/2023Ownership: 0.111%State of Tennessee Treasury DepartmentBought 1,128 shares on 8/15/2023Ownership: 0.053%View All Insider TransactionsView All Institutional Transactions QURE Stock - Frequently Asked Questions Should I buy or sell uniQure stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QURE shares. View QURE analyst ratings or view top-rated stocks. What is uniQure's stock price forecast for 2023? 9 equities research analysts have issued 1 year price objectives for uniQure's shares. Their QURE share price forecasts range from $14.00 to $57.00. On average, they expect the company's share price to reach $44.70 in the next year. This suggests a possible upside of 566.2% from the stock's current price. View analysts price targets for QURE or view top-rated stocks among Wall Street analysts. How have QURE shares performed in 2023? uniQure's stock was trading at $22.67 at the start of the year. Since then, QURE shares have decreased by 70.4% and is now trading at $6.71. View the best growth stocks for 2023 here. Are investors shorting uniQure? uniQure saw a increase in short interest in September. As of September 15th, there was short interest totaling 3,810,000 shares, an increase of 60.8% from the August 31st total of 2,370,000 shares. Based on an average daily trading volume, of 1,030,000 shares, the short-interest ratio is currently 3.7 days. Currently, 8.6% of the shares of the stock are sold short. View uniQure's Short Interest. When is uniQure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our QURE earnings forecast. How were uniQure's earnings last quarter? uniQure (NASDAQ:QURE) posted its earnings results on Tuesday, August, 1st. The biotechnology company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.97 by $4.41. The biotechnology company earned $2.42 million during the quarter, compared to the consensus estimate of $168.66 million. uniQure had a negative net margin of 166.83% and a negative trailing twelve-month return on equity of 44.91%. What ETF holds uniQure's stock ? Global X Genomics & Biotechnology ETF holds 154,612 shares of QURE stock, representing 1.46% of its portfolio. What is Matthew Kapusta's approval rating as uniQure's CEO? 8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees. What other stocks do shareholders of uniQure own? Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE). What is uniQure's stock symbol? uniQure trades on the NASDAQ under the ticker symbol "QURE." How do I buy shares of uniQure? Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is uniQure's stock price today? One share of QURE stock can currently be purchased for approximately $6.71. How much money does uniQure make? uniQure (NASDAQ:QURE) has a market capitalization of $320.07 million and generates $106.48 million in revenue each year. The biotechnology company earns $-126,790,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis. How many employees does uniQure have? The company employs 501 workers across the globe. How can I contact uniQure? uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The official website for the company is www.uniqure.com. The biotechnology company can be reached via phone at (120) 240-6000, via email at investors@uniqure, or via fax at 31-20-566-9272. This page (NASDAQ:QURE) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.